Search Results - (Author, Cooperation:S. Fares)
-
1J. H. Park ; A. H. Goldstein ; J. Timkovsky ; S. Fares ; R. Weber ; J. Karlik ; R. Holzinger
American Association for the Advancement of Science (AAAS)
Published 2013Staff ViewPublication Date: 2013-08-10Publisher: American Association for the Advancement of Science (AAAS)Print ISSN: 0036-8075Electronic ISSN: 1095-9203Topics: BiologyChemistry and PharmacologyComputer ScienceMedicineNatural Sciences in GeneralPhysicsKeywords: Atmosphere/*chemistry ; *Ecosystem ; Mass Spectrometry ; Ozone/analysis/chemistry ; Plants/chemistry ; Volatile Organic Compounds/analysis/*chemistryPublished by: -
2Staff View
Publication Date: 2015-03-27Publisher: Nature Publishing Group (NPG)Print ISSN: 0028-0836Electronic ISSN: 1476-4687Topics: BiologyChemistry and PharmacologyMedicineNatural Sciences in GeneralPhysicsKeywords: Biofuels ; Biomass ; Carbon Dioxide/*metabolism ; *Carbon Sequestration ; Climate Change ; Conservation of Natural Resources/economics/*methods ; Disasters ; Europe ; Fires ; Forestry/economics/*methods ; *Forests ; Trees/classification/*growth & development/*metabolism/parasitology ; WoodPublished by: -
3Ferrara C, Marchi M, Fares S, Salvati L
Italian Society of Silviculture and Forest Ecology
Published 2018Staff ViewPublication Date: 2018-12-17Publisher: Italian Society of Silviculture and Forest EcologyElectronic ISSN: 1971-7458Topics: Agriculture, Forestry, Horticulture, Fishery, Domestic Science, NutritionPublished by: -
4Hakim, Fares S. ; Shetty, Shalesh ; Sidawy, Anton N. ; Curcio, Lisa D. ; Korman, Louis Y. ; Harmon, John W.
Oxford, UK : Blackwell Science
Published 1995Staff ViewISSN: 1524-475XSource: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineNotes: Insulin-like growth factor-I is a polypeptide hormone structurally related to insulin. It is a potent mitogen that promotes growth and differentiation in many tissues. A role for insulin-like growth factor-I in wound healing is suggested by its rapid rise in levels and increased insulin-like growth factor-I messenger RNA expression in tissue after wounding. We designed our study to characterize possible changes in insulin-like growth factor-I receptor binding during wound healing. Surgical wounds created on the abdominal skin of anesthetized New Zealand White rabbits were either left open or closed primarily. Size- and weight-matched specimens were harvested at wounding time (day 0), and at 1, 4, 7, 38, and 50 days after wounding. Preliminary experiments showed that the greatest difference in specific binding occurred between day 0 and day 7. 125I-insulin-like growth factor-I binding studies were performed on frozen tissue specimens and autoradiography was performed and analyzed by computerized densitometry. Scatchard analysis of the binding data showed a single class of insulin-like growth factor-I binding sites whose affinity that is, binding constant (Kd = 0.6 × 10−9) did not change significantly over time; in contrast there was a threefold increase in the number of receptors per milligram tissue in day 7 wound tissue versus normal skin harvested at day 0 (17.3 ± 2.6 × 1010 versus 4.7 ± 2.5 × 1010, respectively, p 〈 0.05). Binding inhibition experiments showed that 125I-insulin-like growth factor-I binding was most specific to insulin-like growth factor-I with insulin-like growth factor-I 〉 insulin-like growth factor-II 〉 insulin. This increase in binding was due to upregulation of insulin-like growth factor-I receptors rather than increased levels of insulin-like growth factor-I binding protein as less than 20% of the threefold increase in binding at day 7 could be attributed to insulin-like growth factor-I binding protein in membrane-free extracts. The presence of specific, high-affinity insulin-like growth factor-I receptors in the skin and their upregulation at day 7 after wounding suggest that insulin-like growth factor-I plays an important role during wound healing.Type of Medium: Electronic ResourceURL: -
5Powell, A.M. ; Albert, S. ; Al Fares, S. ; Harman, K.E. ; Setterfield, J. ; Bhogal, B. ; Black, M.M.
Oxford, UK : Blackwell Science Ltd
Published 2003Staff ViewISSN: 1365-2133Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineNotes: Summary Background Pemphigus is a group of autoimmune blistering diseases of the skin and/or mucous membranes requiring management with immunosuppressive therapy. The optimal therapeutic regimen would rapidly induce remission and maintain effectiveness with minimal adverse effects in the long term. Objectives The present study describes our experience of the addition of mycophenolate mofetil (MMF) to prednisolone in the management of severe, refractory pemphigus. Methods Patients with active, refractory pemphigus were treated with MMF. Our series included 12 cases of pemphigus vulgaris, four cases of pemphigus foliaceous and one case of paraneoplastic pemphigus. All patients were monitored to assess disease control and mycophenolate toxicity. Results Of the 17 cases, MMF has been of benefit to 12. MMF was well tolerated and there were no treatment withdrawals because of safety concerns. Conclusions We found that MMF permitted a reduction in prednisolone dosage without disease relapse.Type of Medium: Electronic ResourceURL: